We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.

Delisted

GBT was delisted on the 4th of October, 2022.

59 hedge funds and large institutions have $1.12B invested in Global Blood Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
59
Holders Change
+59
Holders Change %
% of All Funds
1.65%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
59
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SO
51
STRS Ohio
Ohio
$92K +$104K +2,200 New
Deutsche Bank
52
Deutsche Bank
Germany
$80K +$89.9K +1,906 New
NFA
53
Nationwide Fund Advisors
Ohio
$72K +$80.2K +1,699 New
Barclays
54
Barclays
United Kingdom
$68K +$76.4K +1,620 New
BNP Paribas Financial Markets
55
BNP Paribas Financial Markets
France
$54K +$60.4K +1,281 New
Bank of America
56
Bank of America
North Carolina
$48K +$53.3K +1,129 New
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$17K +$18.9K +400 New
Wells Fargo
58
Wells Fargo
California
$1K +$1.32K +28 New
Citigroup
59
Citigroup
New York
+$94 +2 New

GBT Hedge Fund Activity: Q3 2015 in Review

59 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2015, worth a combined $1.12B.

Buyers outnumbered sellers: 59 funds opened new GBT positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Third Rock Ventures, opening a new position worth an estimated $696M.

  • 59 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2015, up from 0 in Q2 2015.
  • Funds reported $1.12B of Global Blood Therapeutics, Inc. stock for Q3 2015.
  • 59 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2015 and 0 closed out, a net change of +59 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q3 2015 was Third Rock Ventures, an estimated $696M added.

Based on aggregated 13F filings for Q3 2015.